Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
2.830
+0.120 (4.43%)
At close: Mar 9, 2026, 4:00 PM EDT
2.800
-0.030 (-1.06%)
After-hours: Mar 9, 2026, 4:36 PM EDT
Genelux Market Cap
Genelux has a market cap or net worth of $125.33 million as of March 9, 2026. Its market cap has decreased by -23.76% in one year.
Market Cap
125.33M
Enterprise Value
104.26M
1-Year Change
-23.76%
Ranking
Category
Stock Price
$2.83
Market Cap Chart
Since the IPO on January 26, 2023, Genelux's market cap has decreased from $141.69M to $125.33M, a decrease of -11.55%. That is a compound annual growth rate of -3.87%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 120.01M | -26.83% |
| Dec 31, 2025 | 164.02M | 103.78% |
| Dec 31, 2024 | 80.49M | -78.50% |
| Dec 29, 2023 | 374.31M | 164.17% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Spero Therapeutics | 129.58M |
| Cardiff Oncology | 128.53M |
| Aardvark Therapeutics | 127.37M |
| Alpha Cognition | 125.89M |
| Black Diamond Therapeutics | 122.50M |
| Inovio Pharmaceuticals | 119.54M |
| Gain Therapeutics | 117.31M |
| Gossamer Bio | 115.89M |